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Abstract
Background: Previous studies have established that proteinase-activated receptor 2 (PAR2) promotes migration and
invasion of hepatocellular carcinoma (HCC) cells, suggesting a role in HCC progression. Here, we assessed the impact of
PAR2 in HCC stromal cells on HCC growth using LX-2 hepatic stellate cells (HSCs) and Hep3B cells as model.
Methods: PAR2 expression and function in LX-2 cells was analysed by RT-PCR, confocal immunofluorescence, electron
microscopy, and [Ca2+]i measurements, respectively. The impact of LX-2-expressed PAR2 on tumour growth in vivo was
monitored using HCC xenotransplantation experiments in SCID mice, in which HCC-like tumours were induced by
coinjection of LX-2 cells and Hep3B cells. To characterise the effects of PAR2 activation in LX-2 cells, various signalling
pathways were analysed by immunoblotting and proteome profiler arrays.
Results: Following verification of functional PAR2 expression in LX-2 cells, in vivo studies showed that these cells
promoted tumour growth and angiogenesis of HCC xenografts in mice. These effects were significantly reduced when
F2RL1 (encoding PAR2) was downregulated by RNA interference (RNAi). In vitro studies confirmed these results
demonstrating RNAi mediated inhibition of PAR2 attenuated Smad2/3 activation in response to TGF-β1 stimulation in
LX-2 cells and blocked the pro-mitotic effect of LX-2 derived conditioned medium on Hep3B cells. Furthermore, PAR2
stimulation with trypsin or a PAR2-selective activating peptide (PAR2-AP) led to activation of different intracellular
signalling pathways, an increased secretion of pro-angiogenic and pro-mitotic factors and proteinases, and an
enhanced migration rate across a collagen-coated membrane barrier. Silencing F2RL1 by RNAi or pharmacological
inhibition of Src, hepatocyte growth factor receptor (Met), platelet-derived growth factor receptor (PDGFR), p42/p44
mitogen activated protein kinase (MAPK) or matrix-metalloproteinases (MMPs) blocked PAR2-AP-induced migration.
Conclusion: PAR2 in HSCs plays a crucial role in promoting HCC growth presumably by mediating migration and
secretion of pro-angiogenic and pro-mitotic factors. Therefore, PAR2 in stromal HSCs may have relevance as a
therapeutic target of HCC.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide and the second most fre-
quent cause of cancer-related death [1]. Curative liver
transplantation or resection is only possible in approxi-
mately 30 % of patients. For advanced HCC, the multi-
kinase inhibitor sorafenib remains the only approved
chemotherapy agent with survival benefits for advanced
stage HCC patients. However, its use is limited to those
with well-preserved liver function [2–4].
Up to 90 % of cases of HCC develop on the back-
ground of advanced liver fibrosis or cirrhosis, thus repre-
senting a typical inflammation-related cancer type. It is
characterised by a tumour microenvironment where
both tumour cells and stromal cells interact via secretion
of cytokines, proteinases and other biological active fac-
tors. Key players in the organization of an optimal HCC
stromal compartment are activated hepatic stellate cells
(HSCs) [5, 6]. HSCs are characterised by high prolifera-
tion, pronounced matrix proteinase activity and secre-
tion of extracellular matrix (ECM) proteins, as well as of
factors including different proteases that aid in creating
an immunosuppressive, angiogenic and tumour growth-
promoting environment, and thereby critically contrib-
ute to HCC initiation and progression [7–18].
Proteinase-activated receptor 2 (PAR2) [19] belongs to a
group of G protein-coupled receptors (for reviews see: [20–
24]). It can be activated by serine proteinases including tryp-
sin, neutrophil proteinase 3, mast cell tryptase, tissue fac-
tor(TF)/factor VIIa/factor Xa, human kallikrein-related
peptidases and membrane-tethered serine proteinase-1/
matriptase 1 as well as by parasite cysteine proteinases [25]
and cathepsin S [26], but is insensitive to thrombin [21, 23].
Proteolytic cleavage of PAR2 at a specific domain in the
extracellular NH2-terminus unmasks a “tethered ligand” that
interacts with the body of the receptor. In addition, short
synthetic peptides based on the proteolytically revealed re-
ceptor sequences (PAR2-activating peptides; PAR2-APs) and
chemical modified peptide analogues, such as 2-furoyl-
LIGRLO-NH2 [22, 27], can activate PAR2 in the absence of
proteolytic cleavage. Beside a role in regulating physiological
responses ranging from vasoregulation and cell growth to
inflammation and nociception (reviewed in [20, 21, 23, 28,
29]) there is growing evidence for a function of PAR2 in tu-
mours especially from epithelial origin [30–39]. In the set-
ting of liver cancer, it could be demonstrated that PAR2 is
expressed in HCC tissues, different HCC cell lines and pri-
mary HCC cultures established from surgically resected
specimens of primary HCCs, where it stimulates liver car-
cinoma cell migration and invasion via different signalling
pathways including [Ca2+]i mobilisation, Src, Met and p42/
p44 MAPK [40, 41], and is involved in the regulation of
CD47+ HCC stem cells (tumour-initiating cells, TIC) [42].
In addition, TF/factor VIIa/PAR2-signalling cascade seems
to be involved in the modulatory mechanisms of m-TOR-
mediated autophagy in HCC [43]. Overall, these data sug-
gest a role for PAR2 in HCC progression.
At present no information is available about the impact
of PAR2 in stromal cells for HCC development and pro-
gression. However, human HSCs have been shown to ex-
press PAR2 and upon its activation increase the release of
collagen [44] and augment inflammatory and pro-fibrotic
pathways through the induction of pro-inflammatory cy-
tokines and extracellular matrix proteins [45]. This indi-
cates that PAR2 stimulates the activation, proliferation,
collagen production, and TGF-β protein production by
HSCs [45]. Therefore, we specifically addressed this issue
by evaluating the effect of PAR2 silencing in the HSC cell
line LX-2 [46] on tumour growth in a SCID mouse xeno-
graft model, in which a HCC was induced by (co)injection
of LX-2 cells and Hep3B liver carcinoma cells.
Results
PAR2 knockdown inhibits tumour growth in a HCC-SCID
mouse model
Activated HSCs are known to promote HCC growth and
progression [7–18], however, whether HSC-expressed PAR2
is involved here remains unclear. To analyse this, we
employed the human HSC cell line LX-2 in subcutaneous
tumourigenicity experiments in a HCC-SCID mouse
model. Although PAR2 expression by HSCs has been re-
ported [44, 45], specific data for LX-2 cells in this regard
were not available. PAR2 expression was therefore analysed
by PAR2-specific reverse transcription-polymerase chain re-
action (RT-PCR), confocal immunofluorescence and elec-
tron microscopy. Expression was readily detected at both
the mRNA (Fig. 1a) and protein level (Fig. 1b). Granular
PAR2 immunoreactivity was prominently visible around
the nucleus, and to a lesser extent in the peripheral cyto-
plasm and the membrane compartment (Fig. 1b). Mem-
brane localization of PAR2 was also found using scanning
electron microscopy techniques and immunogold labeling
(Additional file 1: Figure S1). To verify that the PAR2 pro-
tein on LX-2 cells is signalling-competent, [Ca2+]i mobil-
isation in response to ligand stimulation was used as an
index for PAR2 activation [47]. We observed a strong ef-
fect of both the synthetic PAR2-AP, 2-furoyl-LIGRLO-
NH2(10 µM), and trypsin (10 nM) on free intracellular cal-
cium (Fig. 1c). The concentration dependency and data
for PAR2 specificity of [Ca
2+]i mobilisation induced by
PAR2-AP are shown in Additional file 2: Figure S2.
Having demonstrated both PAR2 expression and func-
tion, we went on to study the effect of PAR2 knockdown
in LX-2 cells on the growth of tumour xenografts
in vivo. For that purpose, suspensions of cells from the
HCC cell line Hep3B and LX-2 cells (LX-2-wt) stably ex-
pressing a short hairpin (sh) RNA directed against PAR2
(LX-2-shPAR2) and LX-2 cells with a non-target control
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Fig. 1 PAR2 knockdown in LX-2 cells inhibits tumour growth in a SCID mouse model. a-c Expression and function of PAR2 in LX-2 cells. a RT-PCR of
PAR2 expression. Extraction of total RNA from the LX-2-wt cells and synthesis of cDNA was performed as described in the Methods section. PCR
reactions without cDNAs were run as a negative control (Primer). Integrity of the cDNA was independently confirmed by amplification of beta-actin
(Actin). MW marker, molecular-weight marker. Representative results of three independent experiments are shown. b PAR2 immunofluorescence was
detected using the confocal laser scanning microscope LSM-510 Meta (Carl Zeiss, Germany). Localization of immunofluorescence labelled PAR2 is
shown in permeabilized LX-2-wt cells using SAM-11 (1:100) and a FITC-conjugated anti-mouse IgG (1:200) as secondary antibody. c LX-2-wt cells grown
on Lab Tek chambered borosilicate cover glass were loaded with fluo-4-AM as described in Methods. For calcium measurements, an inverted confocal
laser scanning microscope LSM 510 was used. Fluorescence was monitored at 488 nm. (a) PAR2-AP (10 µM) and (b) trypsin (10 nM) induce Ca
2+ rise in
LX-2 cells. (c) Fluorescence images, in pseudocolor, from single LX-2 cells. The sequence shows a fast and transient fluorescence increase from 15 s to
40 s after PAR2-AP addition (0 s). Data represent the mean ± SD from calcium measurements in 20 individual cells, respectively. (d-f) PAR2 knockdown
in LX-2 cells inhibits tumour growth in a SCID mouse model. SCID mice were randomized into five groups, each consisting of 8 animals. Hep3B and
LX-2 cells were subcutaneously (co)injected at the right flank of the mice [(1): 5 × 105 LX-2-wt; (2): 105 Hep3B cells; (3): 105 Hep3B cells plus 5 × 105
LX-2-wt, (4): 105 Hep3B cells plus 5 × 105 LX-2-shCo cells, (5): 105 Hep3B cells plus 5 × 105 LX-2-shPAR2 cells]. d Tumours prepared 16 days after
xenotransplantation. Data for body weight and tumour volume are indicated as mean ± SD (n = 8/group); **p < 0.01). e Representative micro CT
images from the tumours 16 days after xenotransplantation. For 3D reconstruction of the tumours the software “Imalytics” (Philips GmbH, Aachen,
Germany) was used. f Paraffin sections obtained from tumours and stained for hematoxylin/eosin, cytokeratin, Ki67 or CD31. Images were taken at
magnification = × 5 (left panel) and at magnification = × 200
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shRNA, (LX-2-shCo) were injected into the right flank of
SCID mice. After 16 days, tumour formation was evaluated
by macroscopic inspection, micro CT analysis and histo-
chemical/immunohistochemical staining. While injection
of LX-2-wt cells did not result in tumour development
[Fig. 1d, (1)] and Hep3B cell injection alone yielded only
small tumours (tumour volume < 3 mm3) in 2 out of 8 mice
[Fig. 1d, (2)], simultaneous injection of Hep3B and LX-2-wt
cells induced the development of large tumours (tumour
volume approximately 50 mm3) [Fig. 1d, (3)]. Notably, the
tumour promoting effect of LX-2 cells was significantly re-
duced when LX-2-shPAR2 cells were coinjected [Fig. 1d,
(5)] but not with LX-2-shCo cells [Fig. 1d, (4)]. In Fig. 1e,
representative micro CT images are shown for the tumours
that developed under the skin of mice treated with Hep3B
and LX-2-wt cells (3) and with simultaneous injection of
Hep3B and LX-2-shCo cells (4) or LX-2-shPAR2 cells (5).
Histochemical staining of tumour sections from experi-
mental groups (2)-(5) by hematoxylin/eosin showed no
gross differences and revealed histological features of a
HCC with a trabecular growth pattern, central necrosis and
pronounced inflammatory component (Fig. 1f). The epithe-
lial nature of the tumours was confirmed by cytokeratin
staining with the pan-keratin antibody MNF 116 [48].
To further characterise the inhibitory effect of F2RL1 si-
lencing in LX-2 cells on tumour growth, immunohisto-
chemical stainings of Ki67 and CD31 were performed to
analyse tumour cell proliferation and tumour vasculariza-
tion, respectively, both being hallmarks of cancer progres-
sion and tumour growth [49]. As demonstrated in Fig. 1f,
the number of Ki67-positive cells (Hep3B and LX-2 cells)
was apparently higher in tumours induced by coinjection of
Hep3B cells with LX-2-wt cells (or LX-2-shCo) than with
PAR2 deficient LX-2 cells (quantification by manual count-
ing revealed approximately 2.5-fold higher number of Ki67-
positive cells, data not shown), strongly suggesting that the
reduced tumour growth mediated by silencing F2RL1 in
LX-2 cells may depend on diminished cell proliferation in
the tumour microenvironment. Next, we assessed whether
the reduced tumour growth with LX-2-shPAR2 cells corre-
lated with changes in angiogenesis. Therefore, expression of
endothelial marker CD31 in sections from tumours in-
duced by coinjection of Hep3B cells with either wt, shCo or
shPAR2 LX-2 cells were compared. As shown in Fig. 1f,
PAR2 knockdown in LX-2 cells resulted in remarkably re-
duced immunostaining for CD31 indicating that LX-2-
expressed PAR2 promoted angiogenesis. Overall these data
suggest that PAR2 expression in HSCs promotes HCC
growth by increasing cell proliferation and inducing
angiogenesis.
PAR2 knockdown inhibits the pro-mitotic effect of LX-2
cell culture supernatants on Hep3B cells
Having shown the inhibitory effect of F2RL1 silencing in
LX-2 cells on tumour growth in vivo, we sought to reveal
whether reduced proliferation and/or increased apoptosis
of the tumor cells in presence of PAR2-deficient LX-2 cells
may be the underlying mechanism. For this purpose, we
stimulated Hep3B cells with culture supernatants (condi-
tioned for 48 h) from PAR2 depleted LX-2 cells or PAR1 de-
pleted LX-2 cells as control. After incubation of Hep3B
cells with conditioned media from the various LX-2 trans-
fectants for 72 h, vital cell numbers were dramatically lower
in Hep3B cultures which had received conditioned medium
from PAR2 depleted LX-2 cells (Fig. 2). This effect resulted
from reduced proliferation rather than enhanced apoptosis
since the number of non-viable cells, as determined by try-
pan blue exclusion, was not different between the various
cultures (data not shown). These data show that PAR2 but
not PAR1 expressed by LX-2 cells is critically involved in
Fig. 2 PAR2 knockdown inhibits the pro-mitotic effect of LX-2 cell culture supernatants on Hep3B cells. LX-2 cells were treated on two consecutive
days with transfection agent (Lipofectamine 2000) alone (-) or Lipofectamine 2000 plus 50 nM each of a universal control siRNA (Co) or siRNA to PAR1
or PAR2. After the second transfection, cells received normal growth medium which remained on the cells for 48 h. The resulting culture supernatants
from PAR2 or PAR1 depleted and control LX-2 cells were then harvested, cleared by centrifugation and transferred to cultures of Hep3B cells. After a
72 h incubation period with the LX-2 conditioned media, Hep3B cells were detached and cell numbers determined by manual counting and trypan
blue exclusion test. Data represent relative cell numbers (mean ± S.D.) from three independent experiments with cell numbers of Co cells set at 100 %.
* p < 0.05 versus control
Mußbach et al. Molecular Cancer  (2016) 15:54 Page 4 of 16
stimulating growth of Hep3B cells and attest to the above
assumption that reduced tumour growth following F2RL1
silencing in LX-2 cells depends at least in part on dimin-
ished tumour cell proliferation.
PAR2 mediates activation of Src, Met, PDGFR and p42/44
MAPK and promotes TGF-β-induced Smad activation
Based on the results in vivo demonstrating that PAR2
knockdown in LX-2 cells resulted in remarkably reduced
tumour growth in a xenograft SCID mouse model, we set
out to analyse in more detail how PAR2 impacts on LX-2
cells. We first focussed on signalling pathways known to be
triggered by PAR2 activation [24]. PAR2-mediated activation
of different intracellular effectors was monitored by im-
munoblotting. Stimulation of LX-2 cells with the PAR2 ago-
nists trypsin (10 nM) or PAR2-AP (10 μM) caused a
marked increase of phosphorylated (p)-Src (Fig. 3a), p-Met
(Fig. 3b), p-PDGFR (Fig. 3c) and p-p42/p44 MAPK immu-
noreactivity (Fig. 3d and e). To define the PAR2-initiated
phosphorylation sequence, we performed different inhib-
ition experiments. We found in LX-2 cells that trypsin and
PAR2-AP-induced phosphorylation of Met and PDGFR
could be blocked by PP2 (Fig. 3b and c), while the Met in-
hibitor PHA 665752 and the PDGFR antagonist AG 1296
Fig. 3 PAR2 mediates activation of Src, Met, PDGFR and p42/p44 MAPK. LX-2-wt cells were cultured serum-starved for 17 h. a The cells were
treated with PAR2-AP (10 μM) for 3 min and cell lysates were subjected to SDS-PAGE and Western blotting with an anti-phospho-Src antibody
and re-probed with an anti-Src antibody. P-Src = phosphorylated Src, t-Src = total Src. b The cells were treated with PAR2-AP (10 μM) or (b-e) trypsin
(10 nM) for 3 min and cell lysates were subjected to SDS-PAGE and Western blotting with an anti-phospho-Met antibody and re-probed with an anti-
Met antibody. P-Met = phosphorylated Met, t-Met = total Met. c The cells were treated with PAR2-AP (10 μM) or trypsin (10 nM) for 3 min and cell
lysates were subjected to SDS-PAGE and Western blotting with an anti-phospho-PDGFR antibody and re-probed with an anti-PDGFR antibody.
P-PDGFR = phosphorylated PDGFR, t-PDGFR = total PDGFR. Serum-starved LX-2-wt cells were preincubated with d vehicle or the Met receptor tyrosine
kinase inhibitor, PHA 665752 (0.1 μM) for 1 h or e with vehicle or the PDGFR inhibitor AG 1296 (1.0 μM) for 1 h. Following stimulation for 10 min with
the respective receptor agonist cell lysates were immunoblotted with an anti-phospho-p42/p44 MAPK antibody and re-probed with a p42/p44 MAPK
antibody. P-p42/p44 = phosphorylated p42/p44 MAPK, t-p42/p44 = total p42/p44 MAPK. f LX-2-wt cells were depleted of PAR2 or PAR1 protein by
siRNA transfection as described in Fig. 2. Forty-eight hours after the second transfection, the growth medium was removed and replaced by fresh
medium supplemented or not with 10 ng/ml TGF-β1. After 30 min, cells were lysed and immunoblotted with anti-phospho-Smad2/3 antibody and
subsequently with a β-actin antibody to verify equal loading. The phosphorylated forms of Smad2 and Smad3 run as closely spaced bands due to the
slightly lower electrophoretic mobility of Smad2. a-f Quantification of immunoblots was performed by scanning densitometry (Image J 1.43; National
Institutes of Health, Bethesda, Maryland, USA). The data shown in the histograms above the blots are expressed as the fold increase over untreated
control (averages ± S.D.) from three independent experiments. *P-value < 0.05 versus non stimulated control
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were able to inhibit PAR2-mediated phosphorylation of
p42/p44 MAPK (Fig. 3d and e).
TGF-β is overexpressed in HCC [50, 51] and considered
to be a major factor promoting liver carcinogenesis. Spe-
cifically, TGF-β drives transformation of HSCs into myofi-
broblasts [52, 53] as well as their migration and invasion
[54]. PAR2 may enhance these pro-oncogenic effects by
stimulating TGF-β gene expression and protein produc-
tion in HSCs [45]. However, based on recent data from
our group [55], PAR2 may also promote TGF-β signaling
in a more direct fashion in HSCs/LX-2 cells. Indeed, small
interfering RNA (siRNA)-mediated depletion of PAR2 in
LX-2 cells impaired the ability of TGF-β1 to induce C-
terminal phosphorylation of Smad2 and Smad3, reflecting
activation of the pathway, in response to TGF-β1 chal-
lenge (Fig. 3f).
Taken together, these data indicate that PAR2 activation
stimulates a Src-Met/PDGFR-p42/p44 MAPK signalling
axis in LX-2 cells while PAR2 protein expression is re-
quired for activation of TGF-β/Smad signalling.
PAR2 stimulation in LX-2 cells increases secretion of
pro-angiogenic and pro-mitotic factors and proteinases
We next assessed the possibility that PAR2 activation in
LX-2 cells may result in the secretion of pro-mitotic and
pro-angiogenic factors, in turn promoting tumour cell
growth. For this purpose proteome profiler arrays were
employed allowing for simultaneous detection of 55 cyto-
kines and 35 proteinases. Using these arrays for analysis of
culture supernatants of LX-2 cells stimulated with PAR2-
AP or trypsin for 24 h, or non-stimulated LX-2 cells as
control, revealed predominantly enhanced levels of IL-8,
uPA (Fig. 4a), cathepsins V, X, Z, P, MMPs 1, 3, 7, 13 and
ADAMTS1 (Fig. 4b) in supernatants of LX-2 cells treated
with PAR2-AP or trypsin, compared to control cells.
PAR2 activation increases migratory capabilities of LX-2
cells in a Src-, Met-, PDGFR-, p42/p44 MAPK- and MMP-
dependent manner
HSC locomotion is known to be essential for disease
processes in liver including fibrosis and cancer [56, 57].
Fig. 4 LX-2 cells stimulated with PAR2-AP secrete enhanced level of proliferation- and angiogenesis-associated cytokines and proteinases. LX-2-wt
cells, serum-starved for 17 h were treated with PAR2-AP (10 μM), trypsin (10 nM) or vehicle for 24 h and the supernatants were evaluated by
protein analyses using a Human Angiogenesis Array Kit and b Human Protease Array kit as described in the Method section. In the representative
images each pair of horizontal blots (bands) represents a different protein present in the supernatant, whereas the intensities of the blots
characterised the amount of the respective protein (R = reference spot for protein loading). The results in the histograms below the images
represent the mean ± SD for three independent experiments [**indicates a significant difference from non-stimulated (p < 0.05)]
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Specifically, activated HSCs infiltrate HCC stroma and
peri-tumoural tissue during hepatocarcinogenesis where
they secrete substantial amounts of bioactive proteins
[58] thereby facilitating HCC development, progression
and metastasis. Since PAR2 activation in LX-2 cells led
to activation of signalling pathways driving cell motility
(see Fig. 3) and to secretion of pro-invasive proteases
(see Fig. 4), we addressed the question of whether these
events were associated with increased migration of LX-2
cells. Using a boyden-chamber assay, we found that
stimulation of LX-2 cells for 6 h with trypsin or PAR2-AP,
but not with the reverse PAR2-AP (2-furoyl-OLRGIL-
NH2, PAR2-RP), significantly enhanced their migration
(Fig. 5a). As further shown in Fig. 5a, the effect of trypsin
and PAR2-AP on cell migration was absent in LX-2-
shPAR2 cells.
Fig. 5 PAR2 activation mediates enhanced migration of LX-2 cells in a Met-, PDGFR-, Src- kinase-, p42/p44 MAPK- and MMP-dependent manner.
a LX-2 cells (wt, shPAR2 or shCo as indicated) were serum-starved for 17 h and treated with PAR2-AP (10 μM), or trypsin (10 nM) for 6 h. Cells had
migrated through the collagen barrier and the pores of the polycarbonate membrane were fixed, stained and quantified by microscopic
counting. Bars represent the mean values ± S.D. of octuplicates obtained in one experiment, which is representative for three independent assays.
**P-value < 0.05 versus non stimulated control. b Serum-starved LX-2-wt cells were stimulated with PAR2-AP (10 μM) for 4 h and analysis of
plasma membrane filopodial structures was performed using scanning electron microscopy as described in the method section. (a) Cells with
filopodia were quantified in a blinded manner from 100 individual cells per each group and from three experimental preparations. (b) enlarged
inset. The picture shows a single LX-2-wt cell with typical filopodial spike pattern after stimulation with PAR2-AP. c Serum-starved LX-2-wt cells
were preincubated for 1 h with vehicle, SU 11274 (10 μM), PHA 665752 (0.1 μM), AG 1296 (1.0 μM), SL 372 (5.0 μM), PD 98059 (10 μM), U 0126
(10 μM), PP2 (5.0 μM), or GM-6001 (1.0 μM). Cell migration in response to PAR2-AP (10 μM) was analysed after 6 h as described under a.
Representative results from three independent experiments are shown. *P-value < 0.05 versus non stimulated control, **P-value < 0.05 versus
stimulated with PAR2-AP and versus non stimulated control
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It is well known that a migratory phenotype can be as-
sociated with epithelial-mesenchymal transition (EMT),
which in turn involves morphological changes, such as
lamellipodial protrusions and filopodial spikes [59].
Therefore, scanning electron microscopy analyses on the
various LX-2 cells were performed. Interestingly, treat-
ment of LX-2 cells with PAR2-AP or trypsin induced the
formation of filopodia spikes in a significantly larger
number of cells when compared with non-stimulated
controls (Fig. 5b).
To assess the contribution of the PAR2 activated signal-
ling pathways (see Fig. 2) for LX-2 cell migration, we again
performed inhibition studies with a battery of protein
tyrosine kinase and MMP inhibitors. As shown in Fig. 5c,
PP2, PHA 665752 and SU 11274 (another Met inhibitor),
AG 1296, the MEK inhibitors PD 98059, SL 327 and U
0126, and the MMP inhibitor GM-6001 all inhibited the
effect of PAR2-AP on migration of LX-2 cells. Overall,
these data support the view that PAR2 activation increases
the invasive capabilities of LX-2 cells via activation of Src,
PDGFR, Met, p42/p44 MAPK and MMPs.
Discussion
During the last years it became evident that PAR2 plays
an important role in the development, progression and
metastasis of tumours especially from epithelial origin
[30–39, 60]. In case of HCC, studies have focussed on
the function of PAR2 expressed by the tumour cells. This
PAR-subtype is known to promote migration and inva-
sion of HCC cells by stimulating various intracellular
signalling systems including calcium mobilisation, react-
ive oxygen species, Met and p42/p44 MAPK [40, 41].
Moreover, PAR2 is involved in the regulation of CD47
+
HCC stem cells, contributing to tumour initiation, self-
renewal and metastasis [42]. In addition, it could be
shown that the TF/factor VIIa/PAR2-signalling cascade
stimulates m-TOR signalling in liver carcinoma cells and
reduces m-TOR-mediated autophagy induction in
HepG2 xenografts in a SCID mouse model, suggesting a
role in HCC progression [43].
Recent data indicated that also the stromal compart-
ment plays a crucial role in HCC development and pro-
gression and provides an attractive target for HCC
therapy [11, 14]. In the liver, HSCs, fibroblasts, myofi-
broblasts as well as immune and endothelial cells repre-
sent the major cell types of the hepatocyte stromal
microenvironment. Among them, activated HSCs, beside
their well-studied role in liver fibrosis and extracellular
matrix remodeling [61], are discussed as a key driver for
liver cancer development and progression [7–18]. HSC
activation is regulated by complicated networks of nu-
merous growth factors, proteinases, cytokines, integrins
and their cognate receptors including the PAR family
receptors [61, 62]. PAR2 has been shown to stimulate
activation, proliferation, collagen synthesis and TGF-β
production in HSCs and to promote experimental liver
fibrosis [45, 63–65].
In this study, we provide for the first time evidence that
PAR2 in HSCs stimulates HCC growth. This was con-
cluded from the finding that F2RL1 knockdown in hepatic
stellate LX-2 cells inhibited the growth-promoting effect
of these cells in a HCC xenograft SCID mouse model, as
demonstrated by significantly smaller volumes of the tu-
mours established in mice by coinjection of Hep3B and
LX-2 cells depleted of PAR2. In addition, immunohisto-
chemical analyses of these tumours revealed lower indices
for proliferation (reduced immunoreactivity of Ki67 in
both Hep3B and LX-2 cells), and angiogenesis (reduced
CD31 in endothelial cells). This suggests a promoting role
for HSC-derived PAR2 in HCC growth through pro-
proliferative, pro-angiogenic and possibly fibrotic effects
on tumour and stromal cells in the HCC microenviron-
ment. The pro-mitotic effect of HSC-derived PAR2 was
subsequently shown in cell counting experiments with
Hep3B cells stimulated with conditioned media from
PAR2 depleted LX-2 cells. Of note, this growth promoting
effect was specific to PAR2 and was not observed for the
related PAR1. These data are in agreement with the in vivo
data and show that HSCs act on tumour cells through the
release of soluble mitogenic factors. We also observed that
transfection of PAR2 siRNA decreased LX-2 cell numbers
(data not shown), suggesting the possibility that HSC-
derived PAR2 also contributes to tumour growth by
promoting HSC proliferation in a cell-autonomous or
auto-/paracrine manner. Given that activated HSCs are
the major matrix producing cells in the liver, this may sec-
ondarily result in enhanced total matrix accumulation and
eventually fibrosis.
It is now established that HSCs may facilitate HCC de-
velopment, progression and metastasis by different pro-
cesses including migration to the cancer site. More
specifically, during cancer development activated HSCs
infiltrate HCC stroma and peri-tumoural tissue and se-
crete substantial amounts of bioactive proteins [58]
which may act either directly on the cancer cells or help
to establish a microenvironment permissive for HCC
progression. Migration of HSCs is known to be driven
mainly by PDGF/PDGFR-dependent mechanisms [66–68],
including a regulatory role for nitric oxide (NO) and the
small GTPases, Rac1 and Rho [69, 70]. Notably, PAR2 in-
duced the activation of PDGFR and Met following stimu-
lation with PAR2-AP or trypsin, suggesting the possibility
that PAR2 utilizes these pathways to drive the migratory
capacity of LX-2 cells. The importance of this PAR2-
PDGFR-Met crosstalk was further supported by the find-
ing that the PAR2-mediated migration of LX-2 cells was
blocked by AG 1296 and SU 11274/PHA 665752, respect-
ively. In addition, we provided evidence for a role of Src
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and p42/p44 MAPK in PAR2-PDGFR/Met-induced signal-
ling to PAR2-induced invasion in LX-2 cells, since this
could be inhibited by PP2 and SL 327/U 0126, respect-
ively, and stimulation of PAR2 with PAR2-AP or trypsin
induced phosphorylation of Src and p42/p44 MAPK.
Moreover, the PAR2-induced effect on p42/p44 MAPK
could be blocked by AG 1296 and PHA 665752. These re-
sults also demonstrate that the PAR2-triggered phosphor-
ylation of Src is upstream while p42/p44 MAPK is
downstream of PDGFR and Met activation in LX-2 cells.
Our results further indicate that, in addition to a Src-
PDGFR/Met-p42/p44 MAPK signalling axis, MMP activ-
ity seems to be involved in PAR2-mediated invasive effect
on LX-2 cells as concluded from the findings that LX-2
cells treated with PAR2-AP secrete MMPs 1, 3, 7, 13 and
that the MMP inhibitor GM-6001 inhibited the effect of
PAR2-AP and trypsin on LX-2 cell migration.
PAR2 activation augments inflammatory and pro-fibrotic
pathways through the induction of genes encoding pro-
inflammatory cytokines and extracellular matrix proteins
[45]. In line with this, our in vitro experiments with LX-2
cells showed that activated PAR2 not only stimulated cell
migration but also the release of IL-8, uPA, cathepsins,
MMPs and ADAMTS 1. All these factors are known to
contribute to HCC initiation, growth and progression of
HCC by degrading and remodeling the extracellular
matrix and by stimulating angiogenesis and immunomo-
dulation [71–77].
In addition to pro-inflammatory cytokines, TGF-β is
considered a major factor promoting liver carcinogen-
esis. TGF-β1 and TGF-β2 are overexpressed in HCC
[50, 51] and may also drive transformation of HSCs into
myofibroblasts [52, 53] as well as their migration and in-
vasion [54]. Notably, HSCs and LX-2 cells are sensitive
to TGF-β treatment [46, 61], and TGF-β gene expression
and protein production in HSCs is stimulated by PAR2
[45]. Prompted by recent observations in other cell types
[55], we hypothesised that PAR2 expression is also re-
quired for TGF-β signaling in a cell-autonomous man-
ner. To this end, depletion of PAR2 but not PAR1 from
LX-2 cells inhibited the ability of TGF-β1 to activate
Smad2 and Smad3. This suggests that HSC-derived
PAR2, in addition to driving tumour cell and HSC prolif-
eration may promote TGF-β sensitivity of HSCs and, as
a consequence, matrix production.
Evidence for a crucial role for stromal cell-derived
PAR2 in promoting primary tumour growth came also
from mouse models for other solid and stroma-rich can-
cer types. PAR2 deficient mice (harbouring PAR2 defi-
cient stromal cells) exhibit decreased tumour growth
and metastasis in a spontaneous polyoma middle T
(PyMT) breast cancer model [78]. In a mouse model of
pancreatic cancer, stromal PAR2 promoted primary
tumour growth [79]. In tumours resulting from B16
melanoma cells injected subcutaneously, PAR2 limited
primary tumour growth [80]. The role of stromal PAR2
in metastasis, however, appears to be strongly context-
dependent. Stromal PAR2 limited lymph node metastasis
in a spontaneous polyoma middle T (PyMT) breast can-
cer model [78] and in the pancreatic cancer mouse
model [79] but enhanced spontaneous metastasis of B16
melanoma cells injected subcutaneously [80]. Finally,
PAR2 has been shown to play a critical role in stimulat-
ing tumour angiogenesis in the context of mammary
carcinoma [81].
Conclusion
Our study provides novel insight into the function of
PAR2 in HSCs, which may be involved in HCC
growth and progression. PAR2 induces secretion of pro-
angiogenic and pro-mitotic factors and proteinases, dir-
ectly stimulates tumour cell growth in vitro through
secreted factors and activates various signalling pathways
(Src, Met, PDGFR, p42/p44 MAPK) being related to HSC
growth and matrix production. It can be hypothesised that
these mechanisms are of importance in the HCC micro-
environment where both tumoural and stromal cells may
produce PAR2-activating proteinases, like the kallikrein-
related peptidases [82, 83] driving PAR2-mediated effects
in HSCs on HCC growth.
Numerous studies convincingly demonstrate that HSCs
play a critical role in HCC growth and progression [7–18].
From our data on LX-2 cells PAR2 may be concluded as a
player in this scenario. This was supported by preliminary
data demonstrating PAR2 function also in primary cul-
tures of human HSCs (R.K. and H.U., unpublished obser-
vation). Since we used exclusively Hep3B cells as a HCC
cellular model so far, analogous studies with other HCC
cell lines and well-characterised primary HCC cultures are
warranted to confirm the tumour-promoting function of
PAR2 in HSCs.
Our data suggest that targeting PAR2 in HSCs may
have potential for the treatment of this liver carcinoma.
Methods
Reagents
Trypsin (EC 3.4.21.4; 14,700 U/mg) was obtained from
Sigma-Aldrich Chemie GmbH (Steinheim, Germany),
and the selective Met receptor tyrosine kinase inhibitors
PHA 665752 and SU 11274, the PDGFR inhibitor, tyr-
phostin AG 1296, the MAPK (MEK) inhibitors, PD
98059, U0126 and SL 327, the MMP inhibitor GM-6001
(galardin) and the Src inhibitor PP2 were from Calbio-
chem/Merck Biosciences (Bad Soden, Germany). Trypan
blue exclusion tests confirmed that these inhibitors did
not impair cell viability of LX-2 cells (approx. 95 % via-
bility after treatment for 24 h, data not shown). Rabbit
polyclonal anti-phospho-Met-antibody [pYpYpY1230/
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1234/1235] and rabbit polyclonal anti-phospho-PDGFR-
α [Tyr849]/PDGFR-β [Tyr857] were from Life Technolo-
gies GmbH (Darmstadt, Germany), a phosphospecific
monoclonal antibody to p42/p44 MAPK, and rabbit
polyclonal anti-PDGFR-α antibody, C-20, a polyclonal
anti-p42/p44 MAPK antibody, a polyclonal anti- Met
(C12) antibody and a mouse monoclonal anti-PAR2 anti-
body, SAM 11, were from Santa Cruz Biotechnology,
Inc., Heidelberg, Germany. A polyclonal rabbit anti-
phospho-Smad2 (S465/S467)/Smad3 (S423/S425) anti-
body (#AB3226) was from R&D Systems (Wiesbaden,
Germany) and an anti-β-actin antibody from Sigma. A
rabbit polyclonal anti-Src [pY418] antibody was from
BioSource Europe, S.A., Belgium and a monoclonal anti-
Src antibody was from Upstate Biotechnology, Lake Placid,
NY, USA. As secondary antibodies goat anti rabbit IgG-
HRP-conjugated, goat anti mouse IgG-HRP-conjugated
and goat anti rabbit IgG-FITC conjugated (Santa Cruz Bio-
technology, Inc., Heidelberg, Germany) were used. The
PAR2 antagonist GB 88 (5-isoxazoyl-Cha-Ile-spiroindene-
1,4-piperidine), which selectively blocks PAR2 calcium
signalling [84] was a kind gift from Dr. David Fairlie,
(Institute for Molecular Biosciences, University of Adelaide,
Australia).
Peptide synthesis
The PAR1-selective peptide, TFLLRN-NH2, PAR2-AP,
2-furoyl-LIGRLO-NH2 and PAR2-RP 2-furoyl-OLRGIL-
NH2, were synthesised by Fmoc strategy on an ABI-
Peptide-Synthesizer 433A using H-Rink Amide ChemMa-
trix®resin (capacity 0.47 respectively 0.52 mmol/g; PCAS
BioMatrix Inc, Canada). The furoyl-group was coupled
manually with 5 equivalents of acid. The cleavage of the
peptides from resin was performed with trifluoroacetic
acid, 5.0 % H2O und 3.0 % triisopropylsilane. The peptides
were precipitated by diethylether and lyophilized. Crude
synthetic peptides were purified using preparative HPLC
on a 30 × 250 mm Kromasil C18-column with a flow rate
of 40 ml per minute under standard conditions (buffer A:
0.2 % TFA in water, buffer B: 0.2 % TFA in water:acetoni-
trile, 1:4). The purified peptides were dried by
lyophilization and characterised by analytical HPLC and
mass spec analysis on a Voyager-DE PRO workstation.
Cell culture
LX-2 cells (gift from Prof. Scott Friedman, Mount Sinai
School of Medicine, New York, USA) were cultured in
Dulbeccos modified Eagles’s medium (DMEM) supple-
mented with 2.0 % fetal calf serum at 37 °C in a humidified
atmosphere of 5.0 % CO2. The medium was changed every
2–3 days. Hep3B HCC cells (German Collection of Micro-
organisms and Cell Cultures, Braunschweig, Germany,
ACC 325) were routinely cultured in RPMI-1640 supple-
mented with 10 % fetal calf serum at 37 °C in a humidified
atmosphere of 5.0 % CO2. The medium was changed every
2–3 days and for subculturing cells were trypsinised. Since
trypsin itself activates PAR2 the subcultured cells were re-
fed sufficiently to remove all traces of trypsin.
[Ca2+]i measurements
[Ca2+]i was measured in single cells with fluo-4, a fluores-
cence indicator for free Ca2+. Cells were grown on Lab-
Tek™ chambered borosilicate cover glass (Nunc GmbH &
Co. KG, Wiesbaden, Germany) and washed twice with
HEPES buffer (pH 7.4) containing 10 mM HEPES,
145 mM NaCl, 0.5 mM Na2HPO4, 6.0 mM glucose,
1.0 mM MgSO4, 1.5 mM CaCl2. Cells were incubated for
15 min at 37 °C in the same buffer containing 0.5 μM
fluo-4 acetoxymethylester (fluo-4-AM). After loading, the
cells were washed twice and reincubated in HEPES buffer.
For calcium measurement in single cells, an inverted con-
focal laser scanning microscope (LSM 510, Carl Zeiss,
Göttingen, Germany) was used. Fluorescence images were
collected by using the 488 nm argon ion laser line and a
505 nm long pass filter. All fluorescence measurements
were made from subconfluent areas of the dishes, enab-
ling the ready identification of individual cells. Image data
were analysed using the Carl Zeiss AIM software Version
4.2. A selected image in each image set was used as a tem-
plate for designating each cell as a region of interest.
The intracellular calcium concentration was calculated
using the equation [Ca2+]i = 345 (F-Fmin)/(Fmax-F) [85].
The Ca2+ affinity of fluo-4 (Kd) is 345 nM [86]. Fmax was
obtained by addition of 10 μM ionomycin (+6.0 mM
CaCl2), Fmin by addition of 10 mM ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA). The
average of calcium data obtained by measuring 20 cells
was used for calibration.
Reverse Transcription (RT)-PCR analysis
Total RNA was extracted from 1 × 107 LX-2 cells (RNeasy
® Mini Kit, Qiagen GmbH, Hilden, Germany), and for RT-
PCR analysis the Reverse Transcription System (Cat. No.
A 3500) from Promega Corporation (Madison, WI, USA)
was used. For PCR amplification the following primer
pairs were used: forward primer: 5’-TGGATGAGTTTT
CTGCATCTGTCC-3’ and 5’-CGTGATGTTCAGGGCA
GGAATG-3’. The primers were constructed to generate a
fragment of 490 bp for PAR2. PCR amplification was per-
formed with Taq polymerase for 32 cycles at 94 °C for
30 s, 55 °C for 30 s, and 72 °C for 30 s, and, finally 72 °C
for 5 min [87]. Amplified samples were electrophoresed
on a 2.0 % agarose gel containing 0.2 μg/ml SybrGreen
and visualized under UV transillumination. In addition,
PCR products for PAR2 of LX-2 cells were purified and
DNA sequences were determined by 4base lab GmbH,
Reutlingen (Germany).
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Transient transfection of LX-2 cells with PAR2 siRNA and
TGF-β stimulation
For transient silencing of F2RL1, LX-2 cells seeded on
day 1 (2.8 × 105/6-well) underwent two rounds of a 4-h
transfection on days 2 and 3 with 50 nM of siRNA to
PAR2 (Invitrogen) and Lipofectamine 2000 transfection
reagent (Life Technologies). As control, a siRNA to
PAR1 or a universal control siRNA (both from Life
Technologies) was transfected in parallel. Successful
knockdown of PAR2 and PAR1 expression was verified
by quantitative real-time (RT)-PCR as outlined else-
where [55] (data not shown). For sequence information
on siRNAs and PCR primers see [55]. Forty-eight hours
after the second transfection, supernatants to be used
for Hep3B proliferation assays (see below) were col-
lected, centrifuged briefly to remove dead cells and cel-
lular debris and stored frozen until use. The remaining
LX-2 cells were stimulated for 0.5 h with TGF-β1
(10 ng/ml, ReliaTech, Wolfenbüttel, Germany) in normal
growth medium followed by lysis in RIPA buffer con-
taining protease (Boehringer Complete, PMSF)/phos-
phatase (NaF, sodium orthovanadate) inhibitors and
phosphoimmunoblotting for Smad2/3 (see below).
For testing the effect of PAR2 silencing on cell viability,
cells were seeded into 24-well plates and after treatment
with the respective siRNA the viable cells were counted
by trypan blue dye exclusion test.
Generation of LX-2 cells with stable expression of PAR2
small hairpin RNA (shRNA)
Plasmid pLKO.1 vectors encoding shRNA constructs
targeting human PAR2 and plasmid pLKO.1 encoding a
non-targeting control shRNA were obtained from Sigma
(MISSION® shRNA lentivirus-mediated transduction
system, SHCLNG-NM_005242).
To generate lentiviral particles, HEK293T cells were
maintained in DMEM (Biochrom) supplemented with
10 % FCS. The cells were transiently transfected with
the pLKO.1-derived plasmids in combination with pRev,
pEnv-VSV-G and pMDLg using polyethyleneimine. After
12, 24 and 48 h, media containing the retrovirus parti-
cles were collected. LX-2 cells were infected three times
with the particles in the presence of 8.0 μg/ml polybrene.
Forty-eight hours after transduction, transduced cells
were selected with 2.0 μg/ml puromycin. The efficiency
of the knockdown was assessed by quantitative real-time
RT-PCR and by calcium measurements. PCR amplifica-
tion was performed with Maxima Hot Start Taq DNA
Polymerase for 40 cycles at 94 °C for 30 s, 60 °C for 30 s
and 72 °C for 30 s and finally 72 °C for 5 min. Primers
were forward: 5’-TGGATGAGTTTTCTGCATCTGTCC-
3’, and reverse: 5’-CGTGATGTTCAGGGCAGGAATG-3’.
The qPCR was performed on a MasterCycler RealPlex4
(Eppendorf, Hamburg, Germany). All values for PAR2
expression were normalized to those for the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
in the same sample.
For calcium measurements the effect of trypsin and
the PAR2-AP, 2-furoyl-LIGRLO-NH2, on [Ca
2+]i mobil-
isation in PAR2 knockdown-LX-2 cells was investigated
as described above.
Immunofluorescence studies
The expression of PAR2 on protein level was established
using the monoclonal anti-PAR2 antibody SAM-11,
generated against a peptide representing amino acids
37SLIGKVDGTSHVTG50 of human PAR2 (Santa Cruz
Biotechnology). This antibody has been validated for
western blot and immunohistochemical/flow cytometry
procedures [88, 89]. LX-2 cells, grown on glass cover-
slips were washed in TBS containing 4.0 % Tween 20,
fixed with 2.0 % paraformaldehyde in 0.1 M cacodylate
buffer + 4.0 % Tween 20 and washed with 0,1 M glycine
buffer (pH 9.0) as well as with TBS + 4.0 % Tween 20.
Thereafter, the cells were treated with 10 mM citrate
buffer (pH 6.0) in a microwave oven (Miele Supratronic,
M 752) at 80 W, washed in 10 mM Tris/EDTA
(1.0 mM) buffer (pH 9.0), followed by rinsing in TBS.
Then, cells were covered with the secondary antibody
(FITC-conjugated anti-mouse IgG). Control experiments
were carried out under omission of the primary anti-
PAR2 antibody or by using mouse IgG2a instead of
SAM-11. LX-2 cells were analysed using the confocal
laser scanning microscope LSM 510 Meta (Carl Zeiss).
Fluorescence images were collected by using the 488 nm
argon ion laser line.
Field emission scanning electron microscopy (FESEM)
PAR2 immunolabeling
LX-2 cells grown on glass cover slips were washed three
times with PBS, prefixed with 0.1 % glutaraldehyde in
PBS and washed four times in PBS. The cells were incu-
bated 30 min in labeling blocking buffer (LBB): 1.0 %
BSA, 0.5 % gelatin, 0.005 % Tween-20 in PBS, pH 7.2).
For PAR2 immunolabeling, monoclonal anti-PAR2 anti-
body, SAM-11, diluted 1:25 in LBB, and as secondary
antibody, a goat anti-mouse IgG coupled with 20 nm
gold particles (British Biocell International, Cardiff, UK;
1:50) were used. After immunolabeling, the cells were
rinsed in PBS three times and fixed with 2.5 % glutaral-
dehyde in PBS for 30 min. After three washings in PBS
the cells were dehydrated in rising ethanol concentrations
followed by critical point drying and carbon coating in a
BAL-TEC SCD 005 Sputter Coater (BAL-TEC, Balzers,
Liechtenstein). The cells were examined in a LEO 1530
Gemini field emission scanning electron microscope (Carl
Zeiss) at 5 kV acceleration voltage and a working distance
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of 7 mm using a Centaurus scintillation type backscatter
electron detector (K.E. Developments, UK).
Analysis of plasma membrane filopodial structures
LX-2 cells were grown on glass coverslips. After incuba-
tion with PAR2-AP for 4 h, the cells were fixed with
2.5 % glutaraldehyde and subsequently dehydrated as de-
scribed for detection of PAR2 immunolabeling. The cells
were sputter coated with gold and examined in a LEO
1450 VP scanning electron microscope (Carl Zeiss) at
10 kV acceleration voltage and a working distance of
7 mm. In this study, the cells were scored as positive or
negative for filopodial spikes. Filopodia-positive cells
were defined as having more than 10 thin processes be-
yond the cellular edge of the plasma membrane [90].
Quantitative analyses were performed in a blinded man-
ner from 100 individual cells per each group and from
three experimental preparations.
Preparation of cell lysates
The cells were collected by centrifugation at 1000 × g
for 5 min (4 °C), washed with PBS containing bacitracin
(100 μg/ml), PMSF (0.1 mM), pepstatin A (1.0 μg/ml)
and leupeptin (2.0 μg/ml), pH 7.4, and centrifuged again.
The pellet was treated with lysis buffer (PBS, containing
1.0 % (v/v) Triton X-100, 0.5 % (w/v) deoxycholate and
0.1 % (w/v) SDS for 30 min at 4 °C, resuspended and
centrifuged at 30000 × g for 15 min (4 °C).
Protein assay
Protein was determined using the DC Protein Assay Sys-
tem from BioRad Laboratories according to the manu-
facturer instructions.
Analysis of Src, Met, PDGFR, p42/p44 MAPK and Smad2/3
phosphorylation
Immunoprecipitation (IP) and Western blotting
For IP, cleared cell lysates normalized for protein con-
tent were treated with 2.0 μg anti-PDGFR antibody for
2–3 h, followed by 20 μl protein A-Sepharose beads
overnight at 4 °C. Beads were collected by centrifugation,
washed three times with lysis buffer containing 2.0 μg/
ml leupeptin, 1.0 μg/ml pepstatin A, 100 μg/ml PMSF,
100 μg/ml aprotinin, 1.0 mM Na3VO4 and 1.0 mM NaF.
Ten μl Roti®-Load were added to the beads and the sam-
ples were heated for 5 min at 95 °C.
Proteins of cell lysates (Src, Met, p42/p44 MAPK and
Smad 2/3 detection) or immunoprecipitates (PDGFR
detection) were subjected to 10 % SDS-PAGE and trans-
ferred to nitrocellulose membranes (BioRad Laborator-
ies). After blocking in 1.0 % BSA/1.0 % skimmed milk
for 1 h, the nitrocellulose strips were incubated over-
night with the respective first antibody. Strips were
washed two times with 0.05 % Tween 20 washing buffer,
incubated for 45 min with the respective secondary anti-
body conjugated to horseradish peroxidase and washed
again two times as described above. In all experiments,
the immunoblots were stripped and reprobed with anti-
bodies to total protein to confirm equal protein loading.
Secondary antibodies were detected by using the chemi-
luminescence (ECL) Western blotting detection system
(Amersham) and exposure to Kodak X-Omat films.
Immunoreactive bands for phosphorylated forms of
Src (p-Src), Met (p-Met), PDGFR (p-PDGFR),p42/p44
MAPK (p-p42/p44 MAPK), Smad2 and Smad3 (p-
Smad2/3) as well as Src (t-Src), total Met (t-Met), total
PDGFR (t-PDGFR), total p42/p44 MAPK (t-p42/p44
MAPK), and β-actin were quantified using the image
processing program Image J 1.43 (National Institutes of
Health, Bethesda, Maryland, USA).
Proteome profiler arrays
LX-2 cells, serum-starved for 17 h, were treated with
PAR2-AP, 2-furoyl-LIGRLO-NH2, trypsin or vehicle for
24 h. For determination of the relative levels of different
proteins in the supernatant, proteome profiler arrays
[Human Angiogenesis Array Kit, Catalog Number ARY007
(allows to simultaneously detect simultaneously the relative
changes of 55 angiogenesis-associated cytokines: Activin A,
ADAMTS, Angiogenin, Angiopoietin-1, Angiopoietin-2,
Angiostatin/Plasminogen, Amphiregulin, Artemin, Tissue
Factor/Factor III, CXCL16, DPPIV/CD26, EGF, EG-VEGF
Endoglin/CD105, Endostatin/Collagen XVIII, Endothelin,
FGF acidic, FGF basic, FGF-4, FGF-7/KGF, GDNF, GM-
CSF, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IL-1
beta, CXCL8/IL-8, LAP (TGF-beta 1), Leptin, CCL2/
MCP-1, CCL3/MIP-1 alpha, MMP-8, MMP-9, NRG1-
beta 1, Pentraxin 3, PD-ECGF, PDGF-AA, PDGF-AB/
PDGF-BB, Persephin, CXCL4/PF4, PlGF, Prolactin, Serpin
B5/Maspin, Serpin E1/PAI-1, Serpin F1/PEDF, TIMP-1,
TIMP-4, Thrombospondin-1, Thrombospondin-2, uPA,
Vasohibin, VEGF, VEGF-C) and Human Protease Array
Kit, ARY021 (allows to simultaneously detect the relative
changes of 35 proteinases: ADAM8, Cathepsin X/Z/P,
MMP-7, ADAM9, DPPIV/CD26, MMP-8, ADAMTS, Kal-
likrein 3/PSA, MMP-9, ADAMTS13, Kallikrein 5, MMP-
10, Cathepsin A, Kallikrein 6, MMP-12, Cathepsin B,
Kallikrein 7, MMP-13, Cathepsin C/DPPI, Kallikrein 10,
Neprilysin/CD10, Cathepsin D, Kallikrein 11, Presenilin-1,
Cathepsin E, Kallikrein 13,Proprotein, Convertase 9, Ca-
thepsin L, MMP-1, Proteinase 3, Cathepsin S, MMP-2,
uPA/Urokinase, Cathepsin V, MMP-3) R&D Systems,
Minneapolis, MN 55413, USA] were used according to
the manufacturer’s instructions. Briefly, nitrocellulose
membranes were blocked for 1 h and then incubated with
500 μl of supernatant (24 h after treatment with PAR2-AP
or vehicle) overnight at 4 °C. After washing, the mem-
branes were incubated with the detection antibody
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cocktail for 2 h and streptavidin–HRP for 30 min. For data
evaluation, the membranes were exposed to chemilumin-
escent reagents (ECL Plus Western Blotting Detection
System; Amersham) and finally to X-ray films for 30 s.
The developed films were scanned and the average pixel
density of the positive signals was analysed using the ana-
lysis software Image J 1.43 (National Institutes of Health,
Bethesda, Maryland, USA). All images from the arrays
were normalized by subtracting the background and
inverted to eliminate the background differences. To
measure the pixel density, a fixed size rectangular box was
generated around each dot blot/band and the pixel density
was measured. The same sized rectangular box was used
for all bands in all arrays performed. For analysis, the pixel
densities of the negative control on each array were sub-
tracted from the pixel densities obtained from each band
on the array. The data was further converted and normal-
ized into fold change in expression by dividing the pixel
densities of each band by the average pixel densities of the
Streptavidin-HRP reference spots (R) located at the three
corners of each array.
Stimulation of Hep3B cells with LX-2 cell conditioned
media and cell counting
Hep3B cells were seeded in 48-well plates (2 × 104/well).
On the next day, the growth medium was removed and
replaced by 500 μl of cleared culture supernatant condi-
tioned for 48 h by LX-2 cells transfected with either con-
trol siRNA, PAR1 siRNA or PAR2 siRNA (see above:
“Transient transfection of LX-2 cells with PAR2 siRNA
and TGF-β stimulation”). Following incubation with the
LX-2 conditioned media for 72 h, the medium was re-
moved, centrifuged to collect non-adherent cells and the
resuspended pellets combined with the detached adher-
ent cells from the respective well. Then, viable and dead
cells were counted by trypan blue dye exclusion test.
Cell migration assay
LX-2 cell migration was measured using a 48-well
boyden-chamber (NeuroProbe, Inc., Gaithersburg MD,
USA). 51 μl of the cell suspension (4 × 104 cells in
RPMI-1640) with or without inhibitor were placed in
each upper chamber well and 27 μl of cell culture
medium containing the chemoattractant or vehicle in
each lower well. Then, incubation for 6 h at 37 °C in a
humidified incubator with 5.0 % CO2 was performed to
allow cell migration through a porous polycarbonate fil-
ter (6.5 mm in diameter, 8.0 μm pore size) precoated
with collagen (0.35 %). After the incubation period, the
filter was removed, and its upper side was wiped gently
with a cotton tip swab to remove non-migrated cells.
The migrated cells were fixed on the lower surface of
the membrane with 96 % ethanol, stained with Giemsa
solution, and counted under a Zeiss Axiolab microscope.
Data were acquired from three independent experi-
ments, involving octuplicate measurements for each
condition.
Estimation of cell viability
For testing the effect of inhibitors on LX-2 cell viability,
cells were seeded into 24-well plates. Following treat-
ment with the respective inhibitor for 24 h, viable and
non-viable cells were distinguished by trypan blue dye
exclusion method and counted manually. In addition,
this test was used to monitor the viability of LX-2 cells
from cultures used for animal experiments and that of
Hep3B cells incubated with LX-2 culture supernatants.
Animal model
Five to six week-old, male SCID mice (BALB/cJHAN®-
Prkdcscid) were purchased from Harlan Laboratories Ltd.
(Venray, Germany) and were handled under governmen-
tal and institutional rules and regulations after approval
by the respective authorities. Animals were housed
under specific pathogen-free conditions with a 14 h
light/12 h dark cycle and received food and tap water ad
libitum.
Mice were randomised into 5 groups, each group was
consisted of 8 animals. Different cell preparations (cell
viability > 95 %, estimated with trypan blue exclusion
test) were suspended in 200 μl DMEM and subcutane-
ously injected at the right flank of the mice under gen-
eral anesthesia using diethylether [group 1: 5 × 105 LX-2
(wild type) cells, group 2: 105 Hep3B cells; group 3: 105
Hep3B cells plus 5 × 105 LX-2 (wild type) cells, group 4:
105 Hep3B cells plus 5 × 105 LX-2 (non-target control
gene knockdown) cells, group 5: 105 Hep3B cells plus 5 ×
105 LX-2 (PAR2 gene knockdown) cells]. Sixteen days after
xenotransplantation, micro-computed tomography (micro
CT) analyses were performed under isofluorane anesthesia
(CT Imaging, Erlangen, Germany). For 3D reconstruction
of the tumours the software “Imalytics” (Philips GmbH,
Aachen, Germany) was used. Subsequently, tumours were
prepared and macroscopically evaluated. The apparent
tumour volume was calculated using the formula, tumour
volume (mm3) = (length × width2)/2. All tissues were fixed
with paraformaldehyde and embedded in paraffin accord-
ing a standard protocol and routinely stained with
hematoxylin and eosin for histological examination. For
immunohistochemical staining, sections (5.0 μm thick-
ness) cut from paraffin blocks were mounted to glass
slides and stained with the selected markers (monoclonal
mouse anti human cytokeratin antibody, clone MNF 116;
monoclonal mouse anti human Ki67 antigen, clone
MIB-1, DAKO Deutschland GmbH, Hamburg, Deutsch-
land; monoclonal rat anti Mouse CD31 (PECAM-1) anti-
body (DIA310, clone SZ31, Dianova GmbH, Hamburg,
Deutschland).
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The stained slides were scanned and digitally converted
into virtual slides using the Hamamatsu NDP slide scan-
ner (Hamamatsu Nanozoomer 2.HT) and its viewing plat-
form (NDP.Viewer).
Statistical analysis
The data were analysed using SPSS 13 for Windows com-
puter program (SPSS Inc, Chicago, Illinois, USA). Statis-
tical analyses were performed using non-parametric Mann
Whitney U test. A p value <0.05 was considered to be
significant.
Additional files
Additional file 1: Figure S1. PAR2 expression localizes to the plasma
membrane. Immunolocalization of PAR2 on LX-2 cell plasma membrane
by high-resolution field emission scanning electron microscopy. PAR2 was
labeled in LX-2-wt cells with the monoclonal anti-PAR2 antibody SAM-11
in combination with a secondary antibody conjugated to immunogold.
Backscatter electron image of the cellular surface of LX-2 cells with
immunogold-labeled PAR2 complexes (20 nm gold particles, arrowheads).
(TIF 210 kb)
Additional file 2: Figure S2. The effect of PAR2-AP on [Ca
2+]i
mobilisation in LX-2 cells is dose-dependent and can be blocked by the
PAR2 antagonist GB 88. A and B) LX-2-wt cells grown on Lab Tek
chambered borosilicate cover glass were loaded with fluo-4-AM as
outlined in the in Method section. For calcium measurements, an
inverted confocal laser scanning microscope LSM 510 was used and
fluorescence was monitored at 488 nm. A) Dose-response relationship of
PAR2-AP-induced calcium mobilisation. LX-2 cells were stimulated with
PAR2-AP for 15 s at indicated concentrations. Data represent the mean ±
SD from calcium measurements in 20 individual cells and are representative
for 5 independent experiments. B) GB 88 blocks the calcium signal induced
by PAR2-AP, but is unable to inhibit the effect of PAR1-AP on [Ca
2+]i
mobilisation in LX-2 cells. LX-2 cells were preincubated with PAR2 antagonist
GB 88 (10 μM) for 1 h and subsequent stimulated with PAR2-AP (10 μM)
and PAR1-AP TFLLRN-NH2 (100 μM). The arrows indicate the time of addition
of PAR2-AP and PAR1-AP (data are representative for 8 independent
experiments). (TIF 19 kb)
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